“Shockwave C2 Aero makes it easier to navigate tortuous coronary anatomy without relying on additional upfront ancillary devices," said Margaret McEntegart, MD, PhD.
“Shockwave C2 Aero makes it easier to navigate tortuous coronary anatomy without relying on additional upfront ancillary devices," said Margaret McEntegart, MD, PhD.
Orchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”) by the end of Q3 2026
Orchestra BioMed and Medtronic plc, the Company’s strategic collaborator for the BACKBEAT Trial,...
Orchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”) by the end of Q3 2026
Orchestra BioMed and Medtronic plc, the Company’s strategic collaborator for the BACKBEAT Trial,...
The Optiq AI imaging chain common to all six systems uses AI to analyze and optimize image data in real time. The six new systems address a wide range of clinical uses, operational needs, and financial considerations.
The Optiq AI imaging chain common to all six systems uses AI to analyze and optimize image data in real time. The six new systems address a wide range of clinical uses, operational needs, and financial considerations.
“Shockwave C2 Aero makes it easier to navigate tortuous coronary anatomy without relying on additional upfront ancillary devices," said Margaret McEntegart, MD, PhD.
“Shockwave C2 Aero makes it easier to navigate tortuous coronary anatomy without relying on additional upfront ancillary devices," said Margaret McEntegart, MD, PhD.
Patients with the ‘lemon-on-sticks’ phenotype (low BMI/high WHR) showed the strongest signs of congestion, had the highest concentrations of the heart strain biomarker, N-terminal pro-B-type natriuretic peptide, and presented with a...
Patients with the ‘lemon-on-sticks’ phenotype (low BMI/high WHR) showed the strongest signs of congestion, had the highest concentrations of the heart strain biomarker, N-terminal pro-B-type natriuretic peptide, and presented with a...
“We have demonstrated that robotic assistance can be safely and reliably applied to the full spectrum of coronary lesion complexity, including the most challenging anatomies," said Dr. Mohammed Nejjari.
“We have demonstrated that robotic assistance can be safely and reliably applied to the full spectrum of coronary lesion complexity, including the most challenging anatomies," said Dr. Mohammed Nejjari.
- First co-registered and co-aligned IVUS-OCT Platform for Intravascular Imaging
- Company Positioned for U.S. Commercial Launch in a Growing Intravascular Imaging Market Estimated at Over $1 Billion
TORONTO-- Conavi Medical Corp.,...
- First co-registered and co-aligned IVUS-OCT Platform for Intravascular Imaging
- Company Positioned for U.S. Commercial Launch in a Growing Intravascular Imaging Market Estimated at Over $1 Billion
TORONTO-- Conavi Medical Corp.,...
The COMMENCE trial provides prospective, 10-year data demonstrating the durability of Edwards’ RESILIA tissue and its role in lifetime management for patients with aortic stenosis.
The COMMENCE trial provides prospective, 10-year data demonstrating the durability of Edwards’ RESILIA tissue and its role in lifetime management for patients with aortic stenosis.
By integrating the world’s smallest electrical impedance sensor with predictive algorithms into a standard 0.014” guidewire, the Clotild clot-sensing guidewire is designed to provide physicians with real-time, in situ biological intelligence...
By integrating the world’s smallest electrical impedance sensor with predictive algorithms into a standard 0.014” guidewire, the Clotild clot-sensing guidewire is designed to provide physicians with real-time, in situ biological intelligence...
SOUTH SAN FRANCISCO, Calif. -- Cytokinetics, Incorporated announced positive topline results from ACACIA-HCM (Assessment Comparing Aficamten to Placebo on Cardiac Endpoints In Adults with Non-Obstructive HCM), the pivotal Phase 3...
SOUTH SAN FRANCISCO, Calif. -- Cytokinetics, Incorporated announced positive topline results from ACACIA-HCM (Assessment Comparing Aficamten to Placebo on Cardiac Endpoints In Adults with Non-Obstructive HCM), the pivotal Phase 3...
Chicago, IL – Johnson & Johnson announced results from a novel U.S. pilot single-arm trial that evaluated the safety and feasibility of planned Impella 5.5™ support in adult patients undergoing cardiac surgery in the setting of...
Chicago, IL – Johnson & Johnson announced results from a novel U.S. pilot single-arm trial that evaluated the safety and feasibility of planned Impella 5.5™ support in adult patients undergoing cardiac surgery in the setting of...
